▶주메뉴 바로가기
▶본문 바로가기
Samsung Biologics anticipates that S-Tensify will enhance its contract development services by transitioning from traditional Fed-Batch culture methods to high-concentration culture methods with improved productivity. Additionally, Samsung Biologics also launched a rebranded service to boost more ...
A record number of South Korean pharmaceutical and biotech companies are joining this week’s Bio International Convention to showcase their latest innovations and boost client partnerships amid the absence of their Chinese rivals. The event, also known as Bio USA, will run Monday through Thursday...
Lotte Biologics, a South Korean contract development and manufacturing organization, and Merck’s process solutions arm signed a letter of intent for a strategic partnership in biopharmaceutical manufacturing and process development, the company said Friday. Under the partnership, Lotte Biologics ...
German pharmaceutical company Merck Life Science on Wednesday started the construction of a new bioprocessing production center in Daejeon, in which it will invest around 300 million euros ($325 million) -- the company’s largest investment in the Asia-Pacific region. The new bioprocessing product...
Korean biosimilar giant Celltrion announced Thursday that its anti-IgE antibody biosimilar Omlyclo has been approved in Europe, after a series of clinical trials with the reference product Novartis' Xolair. Omlyclo, also called by project name CT-P39, received formal product approval from the Euro...
South Korean stem cell research company Miracell said Thursday that it showcased its stem cell extraction system, Smart M-Cell, at the recent 21st ESSKA congress held in Milan. The biennial European Society for Sports Traumatology, Knee Surgery, and Arthroscopy congress brings together worldwide o...
South Korea’s pharmaceutical companies are accelerating the development of anti-obesity drugs to take share in the rapidly growing market, which is estimated to hit $100 billion by 2030. Hanmi Pharmaceutical is one of a few Korean drug companies that have been pushing ahead with their clinical tr...
Celltrion announced Thursday that the company has won public tenders in Peru to provide its autoimmune disease treatment Remsima (infliximab) and anticancer product Herzuma (trastuzumab) to the South American country. According to Celltrion, Remsima has won a tender held by the Peruvian Workers' I...
Korean biosimilar giant Celltrion said Monday that its Zymfentra, the world’s first subcutaneous formulation of infliximab called Ramsima SC outside the US, has been included in the preferred formulary of Express Scripts, one of the top three pharmacy benefit managers or PMBs in the US. In the US...
LG Chem, South Korea's leading chemical company, unveiled Thursday a new vision to transform into a global top-tier science company, centering on its three business pillars -- electric mobility, sustainable materials and pharmaceuticals. Under the new vision, it has set an ambitious goal of reachi...
Samsung Biologics, a leading contract development and manufacturing organization, announced Wednesday that the company’s earnings in the first quarter this year hit an all-time high. In the January-March period, Samsung Biologics’ sales increased by 31.3 percent on-year to 946.9 billion won ($69...
Celltrion saw the combined market share of its autoimmune biosimilar infliximab products, Remsima and Remsima SC, rising in five European nations, company officials said Tuesday. The combined market share of Remsima and the subcutaneous version of the drug hit 74 percent in Britain, Germany, Franc...
Samsung Bioepis, Samsung Group’s biosimilar arm, announced Friday that the company had started a phase 3 clinical study for SB27, a Keytruda biosimilar. Keytruda is an immuno-oncology drug developed by MSD, a US multinational pharmaceutical company. Indications for the drug include non-small cell...
Daewoong Pharmaceutical has partnered with Chong Kun Dang for local sales of the gastroesophageal reflux disease (GERD) treatment Fexuclue, the country’s 34th new drug, the company said Monday. Fexuclue is a potassium-competitive acid blocker (P-CAB)-based GERD treatment that is designed to impro...
Samsung Bioepis, a biosimilar developer under Samsung Group, announced Monday that the company decided to launch its Soliris biosimilar Epysqli in Korea at a price nearly 50 percent cheaper than the original drug. Epysqli is a biosimilar referencing Soliris, a high-cost drug for the treatment of r...
Posco threads new life to old uniforms for Philippine communities
NCSoft releases sustainability report to meet global green standards
Samsung may supply advanced image sensors for Apple: analyst
Hana chief cleared of severe punishment in DLF crisis
NCSoft launches official Discord channel for Throne and Liberty
Qoo10 liquidity crisis sparks massive complaints, fears of wider damage